Moleculin Biotech Inc. has announced a new collaboration with CIC biomaGUNE, a non-profit research organization in Spain, to conduct preclinical studies on Annamycin for the treatment of glioblastoma multiforme, a form of brain cancer. Under the agreement, Moleculin will provide Annamycin while CIC biomaGUNE, led by Principal Investigator Jesús Ruiz-Cabello, will evaluate the effects of intra-arterial delivery of both liposomal and free Annamycin compared to other treatments in mouse models. This partnership aims to explore new therapeutic options for hard-to-treat brain tumors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-037084), on December 08, 2025, and is solely responsible for the information contained therein.